Ventilator-Induced Lung Injury – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Ventilator-induced lung injury could occur during invasive and non-invasive ventilation and could significantly contribute to the morbidity and mortality of critically ill patients. Though mechanical ventilation can injure both normal and diseased lungs, the latter will suffer far more severe damage due to higher microscale stresses. The terms ventilator-induced lung injury (VILI) and ventilator-associated lung injury (VALI) have been used interchangeably (VALI). The most common mechanisms of ventilator-induced lung injury are alveolar overdistention (volutrauma), barotrauma, atelectotrauma, and inflammation (biotrauma). Other attributed mechanisms include adverse heart-lung interactions, deflation-related, and effort-induced injuries. Even though both strategies result in identical high levels of end-inspiratory pressure and alveolar distension, ventilation with high tidal volume and low or zero PEEP appears to be more harmful than ventilation with low tidal volume and high PEEP. Ventilation of isolated lavaged rat lungs with small tidal volumes (5–6 ml/kg) and low or zero PEEP caused lung injury that increasing PEEP levels could mitigate.

 

The incidence of Ventilator-induced lung injury (VILI) varies from 41 to 57 cases per 100,000 population in the USA.

 

The competitive landscape of Ventilator-Induced Lung Injury includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Ventilator-Induced Lung Injury across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Ventilator-Induced Lung Injury Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Ventilator-Induced Lung Injury – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          PNEUMOSTEM®          Medipost Co Ltd.           Phase 2

2          Infasurf Mallinckrodt      Phase 3

3          SHP607            Shire    Phase 2

4          Furosemide       The Emmes Company, LLC       Phase 2

5          rhCC10 Therabron Therapeutics, Inc.     Phase 2

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more